Savara (SVRA) Other Non Operating Income (2010 - 2026)
Savara (SVRA) reported Other Non Operating Income of $1.7 million for Q1 2026, down 5.01% year-over-year from $1.8 million in Q1 2025, and down 61.12% quarter-over-quarter from $4.4 million in Q4 2025.
Savara (SVRA) Other Non Operating Income (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Other Non Operating Income data on file, last reported at $1.7 million in Q1 2026.
- Other Non Operating Income for Q1 2026 came in at $1.7 million, down 5.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.3 million (up 147.59% YoY), and the FY2025 annual result was $4.7 million, up 9135.29% from the prior year.
- Other Non Operating Income declined to $1.7 million in Q1 2026 per SVRA's latest filing, from $4.4 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $4.4 million in Q4 2025 and troughed at -$254000.0 in Q1 2022.
- A 5-year average of $715588.2 and a median of $146000.0 in 2025 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2022 and 2023: Other Non Operating Income tumbled 345.61% in 2022, then surged 18162.5% in 2023.
- A 5-year view of Other Non Operating Income shows it stood at $668000.0 in 2022, then plunged by 98.2% to $12000.0 in 2023, then soared by 1708.33% to $217000.0 in 2024, then soared by 1922.12% to $4.4 million in 2025, then sank by 61.12% to $1.7 million in 2026.
- Business Quant data shows SVRA's Other Non Operating Income at $1.7 million in Q1 2026, $4.4 million in Q4 2025, and $146000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.71 Mn |
| Dec 31, 2025 | 4.39 Mn |
| Sep 30, 2025 | 146,000.00 |
| Jun 30, 2025 | 1.04 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Dec 31, 2024 | 217,000.00 |
| Sep 30, 2024 | -20,000.00 |
| Jun 30, 2024 | 947,000.00 |
| Mar 31, 2024 | -21,000.00 |
| Dec 31, 2023 | 12,000.00 |
| Sep 30, 2023 | 1.45 Mn |
| Jun 30, 2023 | 33,000.00 |
| Mar 31, 2023 | 29,000.00 |
| Dec 31, 2022 | 668,000.00 |
| Sep 30, 2022 | -8,000.00 |
| Jun 30, 2022 | 42,000.00 |
| Mar 31, 2022 | -254,000.00 |
| Dec 31, 2021 | -77,000.00 |
| Sep 30, 2021 | -574,000.00 |
| Jun 30, 2021 | -489,000.00 |